FT Vest DJIA Dogs 10 Target Income ETF(DOGG.US)

Company Encyclopedia
View More
name
FT Vest DJIA Dogs 10 Target Income ETF
DOGG.US
News
View More

Johnson & Johnson Submits OTTAVA Robotic Surgical System for FDA De Novo Review

Johnson & Johnson has submitted its OTTAVA™ Robotic Surgical System to the FDA for De Novo classification, seeking marketing authorization for various upper abdomen surgeries. This submission is backed by data from a clinical trial at Memorial Hermann-Texas Medical Center. Additionally, the company received IDE approval to start a U.S. clinical trial for inguinal hernia procedures. The OTTAVA system is a multi-specialty soft-tissue surgery robot currently awaiting regulatory approval.

Reuters·
US
JNJ
+1.32%
Reuters·
US
JNJ
+1.32%

Amgen buys Dark Blue Therapeutics in $840m oncology deal

Amgen is acquiring UK-based biotech Dark Blue Therapeutics for up to $840 million, marking the first pharma takeover of 2026. This acquisition will enhance Amgen's oncology pipeline, particularly with the investigational drug DBT 3757 for acute myeloid leukaemia. Analysts believe the integration of Dark Blue's research could strengthen Amgen's early oncology efforts. Following this deal, Amgen also signed a $618 million oncology licensing agreement with DISCO Pharmaceuticals, signaling a renewed focus on dealmaking after a period of inactivity.

Pharmaceutical Technology·
US
AMGN
+3.47%
Pharmaceutical Technology·
US
AMGN
+3.47%

U.S. stock market close | Dow Jones and S&P 500 hit new highs, Hesai Technology rises 10.52% leading the sector

On January 7, 2026, the three major U.S. stock indices closed higher across the board, indicating that the market continues to be optimistic about risk assets. The Dow Jones Industrial Average and the S&P 500 both reached new highs, reflecting positive market sentiment. The automotive parts and equipment sector led the gains due to favorable conditions for new energy vehicles, with leading stock Hesai soaring 10.52%

Market Heartbeat·
Market Heartbeat·

Bayer sues COVID vaccine makers over mRNA technology

Bayer has filed patent infringement lawsuits against COVID-19 vaccine makers Pfizer, BioNTech, and Moderna, claiming they misused its mRNA technology developed in the 1980s. Bayer also sued Johnson & Johnson for using a DNA-based process that allegedly infringes its patent. The lawsuits seek monetary damages but do not aim to halt vaccine production. Bayer's claims add to existing patent disputes in the vaccine industry, with Pfizer and BioNTech reporting significant revenues from their vaccine, Comirnaty, in 2024.

Reuters·
US
BNTX
+2.03%
US
PFE
-0.59%
US
MRNA
+0.64%
Reuters·
US
BNTX
+2.03%
US
PFE
-0.59%
US
MRNA
+0.64%

Shell buys stakes in Angolan offshore blocks from Chevron

Shell has agreed to purchase stakes in two undeveloped offshore blocks in Angola from Chevron. The deal, which includes a 35% interest in Block 49 and 50, has received governmental approval and is pending final legal requirements. This move is part of Shell's strategy to sustain production into the 2030s and grow its gas production by 1% through 2030. Financial details of the transaction were not disclosed.

Reuters·
US
SHEL
-1.87%
US
CVX
-0.86%
US
SHEL.WI
0.00%
Reuters·
US
SHEL
-1.87%
US
CVX
-0.86%
US
SHEL.WI
0.00%
© 2026 Longbridge｜Disclaimer